Modified mRNA Compositions for Cholesterol Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cholesterol-lowering drugs, such as statins and antisense oligonucleotides, pose risks like liver toxicity and inadequate LDL reduction, and do not effectively address cardiovascular outcomes in patients with familial hypercholesterolemia.
Innovation Solution
Development of modified mRNA (mmRNA) compositions encoding LDL receptor mutants deficient in PCSK9 binding and CYP7A1, which are administered to increase cholesterol uptake in hepatocytes and promote its removal through bile acid synthesis, potentially synergizing with statins for enhanced cholesterol excretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current cholesterol-lowering drugs (statins, antisense oligonucleotides) are used, then cholesterol levels are reduced, but liver toxicity occurs and LDL reduction is inadequate
Solution Approach 1:
The patent uses modified mRNA as an intermediary therapeutic agent that encodes PCSK9 binding proteins. These proteins act as mediators between the administered therapy and the LDL receptors, enhancing cholesterol clearance without directly toxicating the liver. The modified mRNA itself serves as a safe carrier that can be engineered to avoid immunogenicity while delivering the therapeutic payload.
Solution Approach 2:
The invention changes the chemical parameters of the therapeutic agent by using modified nucleosides (such as pseudouridine, 5-methylcytidine) in the mRNA sequence. This chemical modification alters the immunogenicity and stability parameters of the RNA, allowing it to evade immune detection while maintaining translational efficiency. The PCSK9 binding protein sequence is also optimized with specific amino acid modifications to enhance binding affinity and stability.
2Quantity of substance
If current cholesterol-lowering drugs are used, then some cholesterol reduction is achieved, but cardiovascular outcomes are not effectively addressed
Solution Approach 1:
The modified mRNA therapy encodes PCSK9 binding proteins that are expressed in advance to prevent PCSK9 from degrading LDL receptors. This preliminary action maintains high levels of functional LDL receptors on hepatocyte surfaces, ensuring continuous and efficient clearance of LDL cholesterol from the bloodstream, thereby preventing cardiovascular damage before it occurs.
3Quantity of substance
If mipomersen is used to lower LDL cholesterol, then LDL levels decrease by more than 20% in half of patients, but serious adverse events including cardiac disorders occur
Solution Approach 1:
The patent employs modified mRNA encoding PCSK9 binding proteins as a safer intermediary approach compared to direct antisense oligonucleotides like mipomersen. The expressed proteins act as soluble mediators that bind PCSK9 in circulation, preventing it from interacting with cell surface LDL receptors. This mechanism achieves potent LDL lowering without the serious adverse events associated with direct RNA interference approaches.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmRNA molecules. The present invention also relates to compositions and methods for altering cholesterol levels using polynucleotides, primary transcripts and mmRNA molecules.